What Is a Normal Vitamin D Level in Perimenopause?

What Is a Normal Vitamin D Level in Perimenopause?

For most perimenopausal women, a 25-hydroxyvitamin D level between 40–60 ng/mL is the functional optimal — not just the 20 ng/mL cutoff labs flag as sufficient. The main caveat: estrogen actively supports vitamin D receptor sensitivity, so as estrogen falls, you may need higher circulating levels to get the same biological effect. The exception is anyone with granulomatous disease or hypercalcemia, where higher vitamin D can cause harm.

---

Why Perimenopause Changes Your Vitamin D Needs

Estrogen and vitamin D are more interconnected than most people realize. Estrogen upregulates the expression of vitamin D receptors (VDRs) in bone, muscle, and immune tissue. As estrogen fluctuates and eventually declines during perimenopause, VDR sensitivity can diminish — meaning your tissues become less responsive to whatever vitamin D is circulating in your bloodstream (Chedraui et al., Maturitas 2010; PMID: 20400250).

At the same time, skin efficiency for synthesizing vitamin D from UVB exposure decreases with age. A 70-year-old synthesizes roughly four times less vitamin D per unit of sun exposure than a 20-year-old. Perimenopause typically begins in the mid-40s, placing most women in a window where both hormonal and cutaneous production are declining simultaneously.

The molecular mechanism behind the estrogen–VDR link is worth understanding in detail. Estrogen response elements (EREs) are present in the promoter region of the VDR gene, which means estradiol directly drives VDR transcription. As estradiol declines during perimenopause — sometimes dropping by 50–70% over a period of several years — VDR gene expression falls proportionally. This is not just a receptor-density issue: lower VDR expression also impairs the downstream genomic signaling that governs calcium transport proteins in the gut, bone matrix proteins, and immune cell differentiation. In practical terms, this means a perimenopausal woman with a 25(OH)D level of 35 ng/mL may have meaningfully worse vitamin D bioactivity than a premenopausal woman with the same number. It is an efficiency problem, not just a supply problem.

The result: a perimenopausal woman eating the same diet, spending the same time outdoors, and taking the same supplements as her 30-year-old self will almost certainly have lower vitamin D levels — and potentially a lower tissue response to those levels.

---

What Lab Reference Ranges Actually Mean

Most commercial labs flag 25-hydroxyvitamin D [25(OH)D] deficiency below 20 ng/mL and insufficiency between 20–29 ng/mL. Sufficiency is reported as ≥30 ng/mL. These thresholds are set primarily for bone health endpoints in general adult populations.

Here's the clinical nuance: the Endocrine Society and several independent researchers have argued that optimal levels for non-skeletal benefits — immune modulation, mood regulation, insulin sensitivity, cardiovascular function — may require 40–60 ng/mL (Holick et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21646368).

For perimenopausal women specifically, aiming for the 40–60 ng/mL range is supported by data linking levels in this zone to reduced hot flash severity, better mood stability, lower fracture risk, and improved insulin sensitivity — all areas of concern during hormonal transition.

If you are also tracking thyroid markers alongside vitamin D, it is worth noting that thyroid function shifts are common in perimenopause and that vitamin D deficiency is independently associated with autoimmune thyroid disease.

---

How Vitamin D Deficiency Manifests in Perimenopause

Symptoms of vitamin D deficiency overlap substantially with perimenopausal symptoms, which is precisely why it gets missed. Fatigue, mood changes, muscle weakness, joint aches, disrupted sleep, and cognitive fog are common to both states. This creates a clinical blind spot: practitioners (and patients) chalk everything up to hormonal transition without checking a vitamin D level.

Research published in Menopause found that perimenopausal and postmenopausal women with 25(OH)D below 30 ng/mL reported significantly higher rates of depressive symptoms, independent of estrogen status (Bertone-Johnson et al., Menopause 2011; PMID: 21278584). Another analysis found that women with low vitamin D had more severe vasomotor symptoms — hot flashes and night sweats — compared to those with adequate levels, with the association remaining significant after adjusting for BMI and physical activity.

A particularly underappreciated consequence is the effect on muscle function. VDRs are expressed in skeletal muscle fibers, and adequate vitamin D is required for muscle protein synthesis and fast-twitch fiber recruitment. Perimenopausal women with levels below 20 ng/mL show measurably lower grip strength and increased fall risk compared to age-matched women with levels above 40 ng/mL, even when controlling for lean mass. This matters because falls and fracture risk rise sharply during the perimenopausal window, and the contribution from subclinical vitamin D insufficiency is frequently underweighted in clinical conversations that focus on estrogen and bone density alone.

Low vitamin D in perimenopause also accelerates bone density loss. Estrogen normally suppresses osteoclast activity; as estrogen declines, bone resorption increases. Vitamin D and calcium absorption are tightly linked — without adequate 25(OH)D, the gut absorbs significantly less calcium, compounding the bone loss that perimenopause already drives.

For women also monitoring estradiol and other hormones, understanding what estradiol levels are normal in perimenopause is useful context for interpreting your vitamin D picture within the broader hormonal transition.

---

How to Test and Track Your Level

The correct test is serum 25-hydroxyvitamin D [25(OH)D], not 1,25-dihydroxyvitamin D (calcitriol). The active form (1,25) is tightly regulated by the kidneys and stays normal even when you are severely deficient in the storage form. Many panels automatically run 25(OH)D, but confirm this with your provider.

Recommended testing frequency for perimenopausal women:

1. Baseline test at the start of perimenopause (or when symptoms emerge)
2. Retest 8–12 weeks after starting or adjusting supplementation
3. Annual maintenance testing once a stable level is achieved
4. Additional testing in winter months if you live above 37°N latitude

Serum calcium and parathyroid hormone (PTH) are useful companion markers. Elevated PTH with low-normal 25(OH)D confirms functional deficiency even if the number appears borderline — PTH rises as a compensatory response when calcium absorption is impaired by low vitamin D, and this secondary hyperparathyroidism can accelerate bone resorption even before 25(OH)D falls into the frankly deficient range. Catching this pattern early gives you a meaningful head start on bone protection. Normal progesterone levels in perimenopause are another marker worth tracking in the same panel, since progesterone also influences bone metabolism during this transition.

---

How Much Vitamin D Do Perimenopausal Women Actually Need?

The RDA for vitamin D is 600 IU for adults under 70. Most vitamin D researchers consider this inadequate for populations at risk of deficiency — and perimenopausal women fit squarely into that category.

A systematic review and meta-analysis found that supplementing with 1,000–4,000 IU daily raised serum 25(OH)D to levels associated with meaningful health outcomes without safety concerns in most healthy adults (Veugelers & Ekwaru, Nutrients 2014; PMID: 25285045). For women starting below 20 ng/mL, loading doses of 4,000–5,000 IU daily for 8–12 weeks followed by a maintenance dose of 2,000 IU are commonly used in clinical practice.

Vitamin D3 (cholecalciferol) is the preferred form over D2 (ergocalciferol). In a head-to-head randomized trial in 335 South Asian and white European women over 12 weeks, D3 was approximately 87% more potent than an equivalent dose of D2 in raising and sustaining serum 25(OH)D (Tripkovic et al., American Journal of Clinical Nutrition 2012; PMID: 22552031). D3 also has a longer half-life in circulation, meaning its benefit persists longer if you miss a dose — practically important for anyone managing a complex supplement schedule.

Critically, vitamin D3 should be paired with vitamin K2 (specifically MK-7, the long-acting form). This is not just marketing — K2 activates matrix Gla-protein (MGP), which prevents calcium from depositing in arterial walls rather than bone. Without K2, aggressive vitamin D supplementation can theoretically increase soft-tissue calcification risk. In the Rotterdam Study, high dietary K2 intake was associated with a 52% reduction in severe aortic calcification and a 57% reduction in aortic calcification mortality over 7–10 years of follow-up (Geleijnse et al., Journal of Nutrition 2004; PMID: 15514282). A dose of 90–180 mcg of MK-7 paired with D3 is the clinically supported approach.

---

Managing Vitamin D Through Diet and Lifestyle

Dietary sources of vitamin D are limited, but meaningful:

For most perimenopausal women, food alone will not close a meaningful deficiency gap. Sun exposure matters, but is highly variable: 10–20 minutes of midday sun on exposed arms and legs can generate 1,000–3,000 IU in fair-skinned individuals at optimal latitudes, but SPF 15 sunscreen reduces synthesis by approximately 99%. Skin pigmentation and BMI also significantly affect conversion efficiency — adipose tissue sequesters vitamin D, effectively reducing bioavailable levels in women with higher body fat percentages.

Lifestyle factors that impair vitamin D status include: obesity (vitamin D is fat-soluble and sequesters in adipose tissue), gastrointestinal conditions affecting fat absorption (celiac disease, Crohn's, post-bariatric surgery), and certain medications including glucocorticoids and anticonvulsants. Magnesium is also a frequently overlooked co-factor: the enzymes that convert vitamin D from its inactive storage form to its active form (both CYP27B1 and CYP24A1) are magnesium-dependent. Studies suggest that adequate magnesium status is necessary for optimal vitamin D metabolism, and that low magnesium can blunt your response to supplementation even when you are taking a well-formulated D3+K2 product (Deng et al., Nutrients 2023; PMID: 36771358).

---

What This Means for Your Formula

Platforms like Ones take a data-driven approach to this exact problem. Because vitamin D dosing is highly individual — depending on baseline 25(OH)D, body weight, sun exposure habits, and concurrent K2 and magnesium status — a personalized formula calibrated to your actual lab results is more precise than any generic daily supplement.

Ones includes Vitamin D3 + K2 (MK-7) as a paired ingredient in its catalog, formulated at clinically relevant doses. The K2 as MK-7 component aligns with the Geleijnse et al. Rotterdam Study evidence on cardiovascular protection from K2-paired supplementation. Rather than defaulting to the standard 600 IU RDA or an arbitrary 5,000 IU dose, Ones' AI practitioner uses your 25(OH)D level to calculate a dose aimed at moving you into the 40–60 ng/mL optimal window — and adjusts on retest.

Given the magnesium dependency of vitamin D metabolism discussed above, Ones also includes Magnesium Glycinate as a highly bioavailable individual active in its catalog — a relevant complement for women whose vitamin D response is blunted. For perimenopausal women also dealing with immune dysregulation, low vitamin D interacts with T-cell regulation and cytokine production; the Immune-C blend can be a relevant addition when immune patterns appear alongside vitamin D insufficiency in your data.

If cholesterol is also on your radar — another marker that shifts during perimenopause — understanding what supplements lower total cholesterol alongside your vitamin D protocol gives a more complete picture of cardiovascular risk management during this transition.

---

Vitamin D and Stress: The Cortisol–Vitamin D Interaction

Stress is a legitimate amplifier of vitamin D insufficiency during perimenopause, and the mechanism is direct: elevated cortisol reduces the renal conversion of 25(OH)D to its active form (1,25-dihydroxyvitamin D) by downregulating CYP27B1 enzyme activity, and chronic HPA axis activation increases vitamin D catabolism through upregulation of the CYP24A1 degradation enzyme. Women who report high perceived stress during perimenopause frequently show lower circulating 25(OH)D than their sun exposure and supplementation habits would predict.

This bidirectional relationship matters for symptom management. Low vitamin D impairs serotonin synthesis — vitamin D regulates the gene encoding tryptophan hydroxylase 2, the rate-limiting enzyme in central serotonin production — and disrupts VDR-mediated GABAergic signaling. Both pathways are linked to mood instability and heightened stress reactivity, which are already amplified during perimenopausal hormonal flux. Correcting deficiency has been shown to modestly reduce anxiety and depressive symptoms in deficient populations in randomized controlled trials, though it is not a standalone intervention for clinical mood disorders (Shaffer et al., Psychosomatic Medicine 2014; PMID: 24632891).

For perimenopausal women managing high cortisol loads, addressing vitamin D correction should be treated as part of a broader HPA axis support protocol — not a replacement for it. The bidirectional vitamin D–cortisol relationship is a real, underappreciated pathway that standard perimenopausal care rarely addresses explicitly, and it is one of the reasons that stress-heavy periods seem to make every perimenopausal symptom worse in ways that are genuinely physiologically grounded.

Tracking hormone-related biomarkers together is more informative than any single number in isolation. Women who are monitoring their hormonal picture during this transition may also find it useful to review what is a normal LH level in perimenopause, since LH patterns are one of the most reliable early indicators of ovarian transition and can contextualize why vitamin D metabolism shifts when it does.

---

Key Takeaways

• The functional optimal 25(OH)D range for perimenopausal women is 40–60 ng/mL — meaningfully higher than the standard lab sufficiency cutoff of 30 ng/mL, and justified by the estrogen–VDR relationship.
• Estrogen decline reduces VDR gene expression, meaning you may need higher circulating vitamin D levels to achieve the same tissue-level effect you had at a younger age — an efficiency problem, not just a supply problem.
• Symptoms overlap heavily: fatigue, mood changes, joint aches, muscle weakness, and sleep disruption are common to both vitamin D deficiency and perimenopause itself — testing 25(OH)D is the only way to separate the two.
• Vitamin D3 paired with K2 (MK-7) is the clinically supported approach; D3 raises levels roughly 87% more effectively than D2, and K2 ensures calcium is directed to bone rather than arterial walls.
• Dosing is highly individual: women starting below 20 ng/mL typically require 4,000–5,000 IU daily for 8–12 weeks, then drop to a 2,000 IU maintenance dose; retest at 8–12 weeks to confirm response, and check PTH and serum calcium alongside 25(OH)D.
• Magnesium and cortisol both affect vitamin D metabolism: low magnesium blunts enzymatic conversion, and chronic stress accelerates vitamin D catabolism — both factors are worth addressing alongside supplementation.

---

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting, stopping, or adjusting any supplement or medication.